Perioperative adjunctive treatment in the management of operable gastric cancer

Journal of Surgical Oncology

Volumn 90, Issue 3, 2005, Pages 174-186

  Silberman, Howard ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Intraoperative radiation; Intraperitoneal chemotherapy; Neoadjuvant chemotherapy

Indexed keywords

5 FLUORO 2'DEOXYURIDINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BEVACIZUMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORDINATED PYRIMIDINE; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 8; IRINOTECAN; MESSENGER RNA; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; NITROSOUREA; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PICIBANIL; PROTEIN BCL 2; PROTEIN P53; PYRIMIDINE DERIVATIVE; SEMUSTINE; TEGAFUR; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; ANGIOGENESIS; BEAM THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; HYPERTHERMIA; IMMUNOTHERAPY; LIVER METASTASIS; META ANALYSIS; NEUTROPENIA; NONHUMAN; PERIOPERATIVE PERIOD; PERITONEAL DIALYSIS; PERITONEUM METASTASIS; PERITONITIS; POPULATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FLUOROURACIL; GASTRECTOMY; HUMANS; LEUCOVORIN; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS;

EID: 19644381297     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20226     Document Type: Conference Paper

References (70)

1. Skipper HE: Laboratory models: Some historical perspective. Cancer Treat Rep 1986;70:3-7.
2. Skipper HE, Schabel FM, Jr., Wilcox WS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964;35:1-111.
3. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
4. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
5. Smith MR, Chabner BA: Systemic chemotherapy of solid tumors. In: Bland KI, Daly JM, Karakousis CP, editors. Surgical oncology: Contemporary principles & practice. New York: McGraw-Hill; 2001. pp 147-158.
6. Carter SK, Bakowski MT, Hellmann K: Chemotherapy of cancer. Third edition. New York: John Wiley & Sons; 1987.
7. Chu E, DeVita VT Jr.: Principles of cancer management: Chemotherapy. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles & practice of oncology. 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2001. pp 289-306.
8. Macdonald JS: Treatment of localized gastric cancer. Semin Oncol 2004;31:566-573.
9. Panzini I, Gianni L, Fattori PP, et al.: Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002;88:21-27.
10. The Gastrointestional Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer: The Gastrointestinal Tumor Study Group. Cancer 1982;49:1116-1122.
11. Cirera L, Balil A, Batiste-Alentorn E, et al.: Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999;17:3810-3815.
12. Estape J, Grau JJ, Lcobendas F, et al.: Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 1991;213:219-221.
13. Neri B, Cini G, Andreoli F, et al.: Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer 2001;84:878-880.
14. Neri B, de Leonardis V, Romano S, et al.: Adjuvant chemotherapy after gastric resection in node-positive cancer patients: A multicentre randomised study. Br J Cancer 1996. 73:549-552.
15. Higgins GA, Amadeo JH, Smith DE, et al: Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer 1983. 52:1105-1112.
16. Engstrom PF, Lavin PT, Douglass HO, Jr., et al.: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 1985. 55:1868-1873.
17. Macdonald JS, Fleming TR, Peterson RF, et al.: Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995;2:488-494.
18. Chipponi J, Huguier M, Pezet D, et al.: Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004;187:440-445.
19. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomised trials. Eur J Cancer 1999;35:1059-1064.
20. Hermans J, Bonenkamp JJ: Meta-analysis of adjuvant chemotherapy in gastric cancer - In reply. J Clin Oncol 1994;12:878-880.
21. Hu JK, Chen ZX, Zhou ZG, et al.: Intravenous chemotherapy for resected gastric cancer: Meta-analysis of randomized controlled trials. World J Gastroenterol 2002;8:1023-1028.
22. Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002;168:597-608.
23. Mari E, Floriani I, Tinazzi A, et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A metaanalysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000;11:837-843.
24. Nakajima T, Ota K, Ishihara S, et al.: Meta-analysis of 10 postoperative adjuvant chemotherapies for gastric cancer in CIH. Jpn J Cancer Chemother 1994;21:1800-1805.
25. Hermans J, Bonenkamp JJ, Boon MC, et al.: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-1447.
26. Sugarbaker PH, Yu W, Yonemura Y: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: The evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003;21:233-248.
27. Fujimoto S, Takahashi M, Mutou T, et al.: Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999;85:529-534.
28. Yu W, Whang I, Chung HY, et al.: Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomized trial. World J Surg 2001;25:985-990.
29. Yu W, Whang I, Suh I, et al.: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998;228:347-354.
30. Kim JY, Bae HS: A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer 2001;4:27-33.
31. Yonemura Y, de Aretxabala X, Fujimura T, et al.: Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study. Hepatogastroenterology 2001;48:1776-1782.
32. Sautner T, Hofbauer F, Depisch D, et al.: Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994;12:970-974.
33. Rosen HR, Jatzko G, Repse S, et al: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 1998;16:2733-2738.
34. Topuz E, Basaran M, Saip P, et al.: Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: A phase II study. Am J Clin Oncol 2002;25:619-624.
35. Allum WH, Hallissey MT, Ward LC, et al.: A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: Interim report. British Stomach Cancer Group. Br J Cancer 1989;60:739-744.
36. Hallissey MT, Dunn JA, Ward LC, et al.: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. Lancet 1994;343:1309-1312.
37. Scaife CL, Calvo FA, Noyes RD: Intraoperative radiotherapy in the multimodality approach to gastric cancer. Surg Oncol Clin N Am 2003;12:955-964.
38. Sindelar WF, Kinsella TJ, Tepper JE, et al.: Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg 1993;165:178-186.
39. Abe M, Nishimura Y, Shibamoto Y: Intraoperative radiation therapy for gastric cancer. World J Surg 1995;19:544-547.
40. Macdonald JS: Clinical overview: Adjuvant therapy of gastrointestinal cancer. Cancer Chemother Pharmacol 2004;54 Suppl 1:S4-11.
41. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
42. Falcone A: Future strategies and adjuvant treatment of gastric cancer. Ann Oncol 2003;14:45-47.
43. D'Angelica M, Gonen M, Brennan MF, et al.: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-816.
44. Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077.
45. Hundahl SA, Macdonald JS, Benedetti J, et al.: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Ann Surg Oncol 2002;9:278-286.
46. Leong T: Evolving role of chemoradiation in the adjuvant treatment of gastric cancer. Expert Rev Anticancer Ther 2004;4:585-594.
47. Leong T, Michael M, Foo K, et al.: Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br J Cancer 2003;89:1433-1438.
48. Sakamoto J, Teramukai S, Nakazato H, et al.: Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: A meta-analysis of centrally randomized controlled clinical trials. J Immunother 2002;25:405-412.
49. Newman E, Marcus SG, Potmesil M, et al.: Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg 2002;6:212-223.
50. Marcus SG, Cohen D, Lin K, et al.: Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg 2003;7:1015-1022.
51. Lowy AM, Feig BW, Janjan N, et al.: A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001;8:519-524.
52. Hartgrink HH, van de Velde CJ, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643-649.
53. Ajani JA, Mansfield PF, Janjan N, et al.: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-2780.
54. Kelsen D, Karpeh M, Schwartz G, et al.: Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996;14:1818-1828.
55. Crookes P, Leichman CG, Leichman L, et al.: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report. Cancer 1997;79:1767-1775.
56. Weese JL, Harbison SP, Stiller GD, et al.: Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): Improved treatment for gastric adenocarcinoma. Surgery 2000;128:564-571.
57. Allum W, Cunningham D, Weeden S: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2003;22:249.
58. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
59. Folkman J: Antiangiogenesis agents. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 6th edition. Philadelphia: Lippincott Williams and Wilkins; 2001. pp 509-519.
60. Erenoglu C, Akin ML, Uluutku H, et al.: Angiogenesis predicts poor prognosis in gastric carcinoma. Dig Surg 2000; 17:581-586.
61. Maeda K, Chung YS, Takatsuka S, et al.: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1995;13:477-481.
62. Kanal T, Konno H, Tanaka T, et al.: Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice. Int J Cancer 1997;71:838-841.
63. Teicher BA, Menon K, Alvarez E, et al.: Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts. In Vivo 2001;15:185-193.
64. Ott K, Vogelsang H, Mueller J, et al.: Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 2003;9:2307-2315.
65. Lenz HI, Leichman CG, Danenberg KD, et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-182.
66. Leichman CG: Thymidylate synthase as a predictor of response. Oncology (Huntingt) 1998;12:43-47.
67. Metzger R, Leichman CG, Danenberg KD, et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
68. Kasprzyk PG, Song SU, Di Fiore PP, et al.: Therapy of an animal model of human gastric cancer using a combination of anti-erbB2 monoclonal antibodies. Cancer Res 1992;52:2771-2776.
69. Applebaum FR: Targeted cancer therapy. In: Foley JF, Vose JM, Armitage JO, editors. Current therapy in cancer. 2nd edition. Philadelphia: W.B. Saunders Company; 1999. pp 525-533.
70. Kim R, Emi M, Tanabe K, et al.: Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 2004;101:2177-2186.